证券时报·2025-11-02 10:07Core Viewpoint - Multiple A-share companies announced significant operational updates, highlighting strategic partnerships and contracts that may impact their future performance [2][5][6]. Group 1: Company Announcements - Betta Pharmaceuticals (300558) announced a strategic partnership with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to obtain exclusive general agency rights for a recombinant coagulation factor product [2][5]. - The partnership aims to enhance Betta's new drug innovation technology platform and expand its product pipeline, with support in R&D, clinical trials, production, registration, and sales promotion [5]. - Betta's subsidiary, Zhejiang Betta Pharmaceutical Sales Co., Ltd., secured exclusive general agency rights for FRSW117, a long-acting recombinant factor VIII product, in the Greater China region [5]. Group 2: Financial Impact - FRSW117 is designed for the treatment of Hemophilia A (HA) patients, with a dosing frequency of once a week for preventive treatment, and has recently completed Phase III clinical trials [5]. - The product is classified as a Class 1 therapeutic biological product, and no domestic long-acting recombinant factor VIII products have been approved for market release yet [5]. - Lan Jian Intelligent (688557) signed a significant operational contract worth 138 million yuan, which is expected to positively impact the company's performance in 2026 [6][8]. - ST Yifei (688646) announced an overseas procurement order valued at approximately 190 million yuan, representing 27.46% of the company's audited revenue for 2024 [8][11].